Yamashita, H.; Nakayama, K.; Kanno, K.; Ishibashi, T.; Ishikawa, M.; Iida, K.; Razia, S.; Kiyono, T.; Kyo, S.
Evaluation of ARID1A as a Potential Biomarker for Predicting Response to Immune Checkpoint Inhibitors in Patients with Endometrial Cancer. Cancers 2024, 16, 1999.
https://doi.org/10.3390/cancers16111999
AMA Style
Yamashita H, Nakayama K, Kanno K, Ishibashi T, Ishikawa M, Iida K, Razia S, Kiyono T, Kyo S.
Evaluation of ARID1A as a Potential Biomarker for Predicting Response to Immune Checkpoint Inhibitors in Patients with Endometrial Cancer. Cancers. 2024; 16(11):1999.
https://doi.org/10.3390/cancers16111999
Chicago/Turabian Style
Yamashita, Hitomi, Kentaro Nakayama, Kosuke Kanno, Tomoka Ishibashi, Masako Ishikawa, Kouji Iida, Sultana Razia, Tohru Kiyono, and Satoru Kyo.
2024. "Evaluation of ARID1A as a Potential Biomarker for Predicting Response to Immune Checkpoint Inhibitors in Patients with Endometrial Cancer" Cancers 16, no. 11: 1999.
https://doi.org/10.3390/cancers16111999
APA Style
Yamashita, H., Nakayama, K., Kanno, K., Ishibashi, T., Ishikawa, M., Iida, K., Razia, S., Kiyono, T., & Kyo, S.
(2024). Evaluation of ARID1A as a Potential Biomarker for Predicting Response to Immune Checkpoint Inhibitors in Patients with Endometrial Cancer. Cancers, 16(11), 1999.
https://doi.org/10.3390/cancers16111999